Macquarie Group
ADMS

Macquarie Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Macquarie Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,799,420
Closed -$5.2M – 2423
2020
Q1 		$5.2M Sell
1,799,420
-367,996
-17% -$1.65M 0.01% 706
2019
Q4 		$8.21M Sell
2,167,416
-93,262
-4% -$446K 0.01% 685
2019
Q3 		$11.6M Sell
2,260,678
-151,480
-6% -$935K 0.02% 575
2019
Q2 		$15M Sell
2,412,158
-209,542
-8% -$1.21M 0.03% 527
2019
Q1 		$18.6M Sell
2,621,700
-86,517
-3% -$778K 0.03% 478
2018
Q4 		$23.1M Buy
2,708,217
+923,099
+52% +$12M 0.04% 392
2018
Q3 		$35.7M Buy
1,785,118
+474,808
+36% +$11.1M 0.06% 345
2018
Q2 		$33.8M Buy
1,310,310
+145,412
+12% +$4.03M 0.06% 356
2018
Q1 		$27.8M Buy
1,164,898
+273,936
+31% +$8.64M 0.05% 387
2017
Q4 		$30.2M Buy
890,962
+139,934
+19% +$3.91M 0.05% 370
2017
Q3 		$15.9M Buy
+751,028
New +$13.8M 0.03% 502

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Macquarie Group's ADMS Position: Q2 2020 in Review

Macquarie Group sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 1,799,420 shares — an estimated $5.2M sold.

Macquarie Group first reported a position in ADMS in Q3 2017 and held it in 11 quarters. The position peaked at $35.7M in Q3 2018. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Macquarie Group reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Macquarie Group sold 1,799,420 Adamas Pharmaceuticals shares in Q2 2020, an estimated $5.2M.
  • Macquarie Group first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 11 quarters.
  • Macquarie Group's Adamas Pharmaceuticals position peaked at $35.7M in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Macquarie Group's 13F filing for Q2 2020, filed 11 Aug 2020.